The impact of BCR‐ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia
A Ercaliskan, AE Eskazan - Cancer, 2018 - Wiley Online Library
Although the majority of patients with chronic myeloid leukemia do well with treatment with
tyrosine kinase inhibitors (TKIs), some patients still have inferior outcomes. There are many …
tyrosine kinase inhibitors (TKIs), some patients still have inferior outcomes. There are many …
BCR–ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells
N Ueda, R Zhang, M Tatsumi, TY Liu… - Cellular & Molecular …, 2018 - nature.com
The advent of tyrosine kinase inhibitor (TKI) therapy markedly improved the outcome of
patients with chronic-phase chronic myeloid leukemia (CML). However, the poor prognosis …
patients with chronic-phase chronic myeloid leukemia (CML). However, the poor prognosis …
[引用][C] Analysis of C-peptide-specific CD4+ T cells in the peripheral blood of people with type 1 diabetes
M So - 2018 - The University of Melbourne